Additionally, the combination of these inhibitors effectively targets critical components in the PI3K/AKT and EGFR/MEK/ERK pathways, resulting in enhanced apoptosis, reduced tumor growth, and bypassing compensatory activation. This evidence concerns the gene AKT1 and neoplasm.